drugset / Trial / NCT07075718

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07075718

Phase 2/3 Recruiting 610 enrolled Glaukos Corporation
RandomizedSequentialTriple-blindTreatment

Summary

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Timeline

Start
2025-06-12
Primary completion
2028-03
Completion
2032-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Timolol Other / unclassified 0.5 % Other
Subject Travoprost Other / unclassified Other

Indications